Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03057054 |
|
Recruitment Status :
Active, not recruiting
First Posted : February 17, 2017
Last Update Posted : June 30, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hematopoietic and Lymphoid System Neoplasm Leukemia Lymphoma Plasma Cell Myeloma | Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Biological: Lactobacillus plantarum strain 299 Biological: Lactobacillus plantarum strain 299v Other: Placebo Administration | Phase 3 |
PRIMARY OBJECTIVE:
I. To determine efficacy of orally-administered Lactobacillus plantarum (LBP) in preventing the development of gastrointestinal (GI) acute graft versus host disease (aGvHD) in children and adolescents undergoing alternative donor allogeneic hematopoietic cell transplantation (alloHCT).
EXPLORATORY OBJECTIVES:
I. To determine whether orally-administered LBP decreases the incidence of grade II-IV aGvHD following alternative donor alloHCT.
II. To determine whether LBP administration maintains intestinal integrity as measured by mean serum citrulline levels and reduction in mucosal barrier injury (MBI) bacteremia.
III. To measure the effects of LBP on the intestinal flora phylogenetic composition during and after alternative donor alloHCT using 16S ribosomal ribonucleic acid (rRNA) gene deep sequencing.
IV. To measure effects of LBP on intestinal flora function during and after alternative donor alloHCT using metagenomic and metabolite profiling.
V. To measure proposed immunomodulatory effects of LBP in mean serum levels of alloreactive-induced inflammatory cytokines (IL-2, IL-6, IL-12p70, IFN gamma, TNF alpha, etc) in patients receiving LBP compared to placebo.
VI. To determine whether LBP administration reduces the incidence of Clostridium difficile-associated diarrhea in alternative donor HCT patients.
VII. To determine whether LBP administration reduces hospital days within the first 120 days post hematopoietic cell transplant (HCT).
VIII. To define the safety of orally administered LBP strains 299 and 299v in alternative donor HCT patients as measured by incidence of Lactobacillus plantarum bacteremia.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive Lactobacillus plantarum strains 299 and 299v orally (PO) or through nasojejunal (NJ), nasogastric (NG) or gastronomy (G) tube once daily (QD) on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
ARM II: Patients receive placebo PO or through NJ, NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
After completion of study treatment, patients are followed up for 120 days from alloHCT.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 500 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Prevention |
| Official Title: | The Effectiveness of Lactobacillus Plantarum (LBP, IND# 17339) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT) |
| Actual Study Start Date : | April 30, 2018 |
| Estimated Primary Completion Date : | September 30, 2022 |
| Estimated Study Completion Date : | September 30, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Arm I (Lactobacillus plantarum, alloHCT)
Patients receive Lactobacillus plantarum strains 299 and 299v PO or through NJ, NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
|
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Undergo alloHCT
Other Names:
Biological: Lactobacillus plantarum strain 299 Given PO or via NJ, NG or G tube
Other Name: DSM 6595 Biological: Lactobacillus plantarum strain 299v Given PO or via NJ, NG or G tube
Other Names:
|
|
Placebo Comparator: Arm II (placebo, alloHCT)
Patients receive placebo PO or through NJ, NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
|
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Undergo alloHCT
Other Names:
Other: Placebo Administration Given PO or via NJ, NG or G tube |
- Incidence of stage 1-4 gastrointestinal (GI) acute graft versus host disease (aGVHD) [ Time Frame: Up to 120 days post stem cell infusion ]The proportion of eligible patients having stage 1-4 GI aGvHD incidence from Day 0 through Day 120 will be compared between the two arms.
- Incidence of grade II-IV overall graft versus host disease [ Time Frame: Up to 120 days post stem cell infusion ]Similar analysis approach will be used as described for the primary outcome measure but using the dichotomous cumulative incidence of grade II-IV acute graft versus host disease as the endpoint measure.
- Incidence of blood stream infection [ Time Frame: Up to 120 days post stem cell infusion ]The incidence of mucosal barrier blood stream infections will be compared between two groups.
- Incidence of Clostridium difficile-associated diarrhea [ Time Frame: Up to 120 days post stem cell infusion ]Proportion of C. diff during the study period will be compared between arms.
- Plasma levels of citrulline [ Time Frame: Up to 120 days post stem cell infusion ]The citrulline levels at each of the time points will be summarized and described by arm.
- Graft versus host disease biomarkers [ Time Frame: Up to 120 days post stem cell infusion ]Descriptive analysis will be used to examine the association between graft versus host disease outcomes and bacterial genes, pathways, and metabolites.
- Blood/stool measures of intestinal flora assessed using sequencing [ Time Frame: Up to 120 days post stem cell infusion ]The association between Lactobacillus plantarum administration and bacterial genes and pathways, and bacterial metabolites will be evaluated.
- Laboratory correlative measures for allogeneic-induced inflammation [ Time Frame: Up to 120 days post stem cell infusion ]The effects of Lactobacillus plantarum on pro-inflammatory (LBP) cytokines in allogeneic hematopoietic cell transplantation recipients will be examined.
- Hospital days [ Time Frame: Up to 120 days post stem cell infusion ]Total hospital days over the study period is calculated as the duration between the date of admission for conditional therapy and the date of discharge (or the study end date). Hospital days will be compared between arms.
- Incidence of Lactobacillus plantarum bacteremia [ Time Frame: Up to 120 days post stem cell infusion ]Patients who have at least one incidence (positive) of Lactobacillus plantarum during any reporting period is considered evaluable for this aim. The proportion of C. diff during the study period will be compared between arms.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 2 Years to 25 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- All clinical and laboratory studies, if applicable, must be obtained within 21 days prior to start of protocol therapy (repeat if necessary); protocol therapy must begin within 6 months of study enrollment
- Patient must have a diagnosis that is managed with an alternative donor allogeneic hematopoietic cell transplant
- Patients must have a Lansky (for patients =< 16 years of age) or Karnofsky (for patients > 16 years of age) performance status score of >= 70; patients who are unable to walk because of a chronic underlying condition (such as paralysis), but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing performance score
-
Hematopoietic cell transplant (HCT)
-
Patient must be receiving cells from alternative donor defined as one of the following:
- Unrelated donor with a complete human leukocyte antigen (HLA) match or a 1 or 2 HLA mismatch, considering only HLA-A, HLA-B, HLA-C, and HLA-DRB1
- Related donor with a 1 or more HLA mismatch (including haplo-identical)
- Note: History of HCT or other cellular therapy (e.g. chimeric antigen receptor [CAR]-T cells, donor lymphocyte infusions) is permitted
-
Exclusion Criteria:
- Patient plans on receiving stem cells from a matched (8/8) related donor
- Patient has used a probiotic dietary supplement within the previous 30 days of enrollment; (consumption of yogurt products is allowed)
- Patient has a history of severe GI tract insult including but not limited to previous bowel perforation, grade 4 neutropenic colitis or typhlitis, inflammatory bowel syndrome, short small bowel syndrome (Crohn's disease, ulcerative colitis), history of gastrointestinal GVHD, or history of bowel resection
- Patient has a medical, psychiatric or social issue that would compromise patient safety or compliance with protocol therapy, or interfere with consent, study participation, follow up, or interpretation of study results
- Female patients who are pregnant are not eligible; women of childbearing potential require a negative pregnancy test prior to enrollment
- Patient has diarrhea at the time of enrollment which is Clostridium difficile toxin positive
- Patient is receiving antibiotic therapy for an active bacterial infection
- Patient is allergic to all third or fourth generation cephalosporins, carbapenems, and all aminoglycosides, which are used to empirically treat LBP bacteremia
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03057054
Show 43 study locations
| Principal Investigator: | Michael L Nieder | Children's Oncology Group |
| Responsible Party: | Children's Oncology Group |
| ClinicalTrials.gov Identifier: | NCT03057054 |
| Other Study ID Numbers: |
ACCL1633 NCI-2017-00208 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) ACCL1633 ( Other Identifier: Children's Oncology Group ) COG-ACCL1633 ( Other Identifier: DCP ) ACCL1633 ( Other Identifier: CTEP ) R01CA201788 ( U.S. NIH Grant/Contract ) UG1CA189955 ( U.S. NIH Grant/Contract ) |
| First Posted: | February 17, 2017 Key Record Dates |
| Last Update Posted: | June 30, 2022 |
| Last Verified: | June 2022 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Multiple Myeloma Neoplasms, Plasma Cell Graft vs Host Disease Immune System Diseases Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases |
Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders |